A recent study published in Quaternary Research describes the discovery and identification of possible aardvark tracks and ...

While earlier weather-forecasting AIs have replaced some tasks done by traditional models, new research uses machine learning ...

Morgan Stanley initiated coverage of Aardvark Therapeutics (AARD) with an Overweight rating and $29 price target The firm believes the Phase 2 ...

Cantor Fitzgerald initiated coverage of Aardvark Therapeutics (AARD) with an Overweight rating and $50 price target Aardvark is developing ...

Equities research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Aardvark Therapeutics in a report released on Monday, March 10th. Cantor Fitzgerald analyst J ...

Cantor Fitzgerald assumed coverage on shares of Aardvark Therapeutics (NASDAQ:AARD – Free Report) in a report issued on Monday morning, Marketbeat reports. The brokerage issued an overweight rating ...

The firm expressed optimism about Aardvark’s lead drug, ARD-101, which is currently in phase 3 trials for Prader-Willi syndrome (PWS), a rare genetic disorder with no approved treatments.

Scientists have uncovered an extremely rare fossil discovery along South Africa’s Cape coast, revealing traces of a ...

In February, three new businesses opened, including a long-awaited restaurant. However, three businesses are on the way out ...